Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) CEO Dr Vladislav Sandler talked with Proactive's Stephen Gunnion about a significant milestone for the company: the opening of its first clinical trial site and the commencement of patient recruitment for its lead drug, HG-CT-1. This Phase 1 trial is designed to evaluate the safety profile of HG-CT-1, a CAR-T therapy aimed at treating relapsed and refractory acute myeloid leukaemia (AML) in adult patients.
Sandler highlighted the trial's objectives, which include assessing the therapy's efficacy based on AML-specific response criteria, overall survival, progression-free survival, and duration of response. He emphasised that this trial represents a major step forward in offering hope to patients with limited treatment options. The trial is being conducted at a top-tier cancer research institution in the United States.
Discussing future plans, Sandler revealed that the company intends to expand trials to include pediatric patients with AML and acute lymphoblastic leukaemia, as well as patients suffering from the rare blood disease BPDCN. These efforts underline Hemogenyx's commitment to revolutionizing treatments for these conditions.